RxDoctor Payments Data

Stephen Holzman, MD

Psychiatry · Glastonbury, CTNPI 1821050915

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 30 payments — averaging $55.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$690
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$283
  • Johnson & Johnson$265
  • AbbVie$183
  • Neurocrine Biosciences, Inc.$115
  • Lundbeck LLC$44
  • plus $84 from 3 others

What the payments were for

  • Food & beverage$1,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,665 in reported general payments places this provider in the 80th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,780
Medicare patients
37
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole25$44,327
VraylarCariprazine Hcl20$33,198
Aripiprazole21$4,294
VyvanseLisdexamfetamine Dimesylate11$4,198
Bupropion XlBupropion Hcl164$3,650
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine64$1,644
Clonazepam190$1,102
Duloxetine Hcl40$990
Methylphenidate Hcl23$882
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$733
Eszopiclone14$656
Trazodone Hcl90$630
Quetiapine Fumarate20$519
Alprazolam105$501
Lorazepam60$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$690$44,32725 claims
AbbVieVraylar$183$33,19820 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$42$4,19811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Glastonbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →